vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.
Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $37.2M, roughly 1.0× GYRE THERAPEUTICS, INC.). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -3.7%, a 272.4% gap on every dollar of revenue. On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs 33.4%). Over the past eight quarters, Orchid Island Capital, Inc.'s revenue compounded faster (301.6% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
GYRE vs ORC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $38.5M |
| Net Profit | $-1.4M | $103.4M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | — |
| Net Margin | -3.7% | 268.7% |
| Revenue YoY | 33.4% | 372.6% |
| Net Profit YoY | -340.1% | 1764.9% |
| EPS (diluted) | $-0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $38.5M | ||
| Q3 25 | $30.6M | $26.9M | ||
| Q2 25 | $26.8M | $23.2M | ||
| Q1 25 | $22.1M | $19.7M | ||
| Q4 24 | $27.9M | — | ||
| Q3 24 | $25.5M | $340.0K | ||
| Q2 24 | $25.2M | $-697.0K | ||
| Q1 24 | $27.2M | $-2.5M |
| Q4 25 | $-1.4M | $103.4M | ||
| Q3 25 | $5.9M | $72.1M | ||
| Q2 25 | $1.6M | $-33.6M | ||
| Q1 25 | $3.7M | $17.1M | ||
| Q4 24 | $569.0K | — | ||
| Q3 24 | $2.9M | $17.3M | ||
| Q2 24 | $4.5M | $-5.0M | ||
| Q1 24 | $9.9M | $19.8M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 22.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | 12.7% | — | ||
| Q1 24 | 29.7% | — |
| Q4 25 | -3.7% | 268.7% | ||
| Q3 25 | 19.4% | 267.8% | ||
| Q2 25 | 5.9% | -145.0% | ||
| Q1 25 | 16.9% | 86.9% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 11.2% | 5094.1% | ||
| Q2 24 | 18.0% | 714.3% | ||
| Q1 24 | 36.6% | -794.2% |
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $665.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $1.4B |
| Total Assets | $166.1M | $11.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $665.9M | ||
| Q3 25 | $60.0M | $583.9M | ||
| Q2 25 | $54.4M | $440.8M | ||
| Q1 25 | $29.9M | $396.4M | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $25.1M | $322.1M | ||
| Q2 24 | $25.1M | $241.0M | ||
| Q1 24 | $37.4M | $190.4M |
| Q4 25 | $106.0M | $1.4B | ||
| Q3 25 | $101.9M | $1.1B | ||
| Q2 25 | $92.0M | $912.0M | ||
| Q1 25 | $68.1M | $855.9M | ||
| Q4 24 | $63.3M | — | ||
| Q3 24 | $63.2M | $656.0M | ||
| Q2 24 | $60.4M | $555.9M | ||
| Q1 24 | $56.6M | $481.6M |
| Q4 25 | $166.1M | $11.7B | ||
| Q3 25 | $159.4M | $9.1B | ||
| Q2 25 | $152.6M | $7.6B | ||
| Q1 25 | $129.8M | $7.3B | ||
| Q4 24 | $125.4M | — | ||
| Q3 24 | $125.2M | $5.9B | ||
| Q2 24 | $120.9M | $4.9B | ||
| Q1 24 | $122.0M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $120.4M |
| Free Cash FlowOCF − Capex | $-5.8M | — |
| FCF MarginFCF / Revenue | -15.5% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $120.4M | ||
| Q3 25 | $4.7M | $28.0M | ||
| Q2 25 | $2.1M | $18.4M | ||
| Q1 25 | $-129.0K | $25.8M | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $1.7M | $-14.8M | ||
| Q2 24 | $-5.5M | $19.3M | ||
| Q1 24 | $2.9M | $45.0M |
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-251.0K | — | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $2.7M | — |
| Q4 25 | -15.5% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -10.1% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | -27.5% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | 1.16× | ||
| Q3 25 | 0.79× | 0.39× | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | 1.51× | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | -0.86× | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | 2.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
